News
ESMO: NIAGARA backs Imfinzi in bladder cancer, but will FDA?
AstraZeneca has revealed the data for Imfinzi in muscle-invasive bladder cancer (MIBC) that it hopes will be enough to secure FDA approval – although the jury is out on that.
